Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 1, 2012, Pages 57-63

  Molnari, Jillissa C ^a   Hassan, Hazem E ^b,c   Myers, Alan L ^a  

^a DRAKE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Helwan   (Egypt)

Author keywords

Bupropion; CYP2B6; Drug interaction; Pharmacokinetics; Sertraline

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B; RADAFAXINE; SERTRALINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENCEPHALE ISOLE; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BRAIN; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; MICE; OXIDOREDUCTASES, N-DEMETHYLATING; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TISSUE DISTRIBUTION;

EID: 84857656177     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0065-6     Document Type: Article

References (33)

1. AJ Bailer 1988 Testing for the equality of area under the curves when using destructive measurement techniques J Pharmacokinet Biopharm 16 3 303 309 3221328 10.1007/BF01062139 1:STN:280:DyaL1M7isFeltg%3D%3D
2. MN Beyens C Guy G Mounier S Laporte M Ollagnier, et al. 2008 Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004 Drug Saf 31 11 1017 1026 18840021 10.2165/00002018-200831110-00006 1:CAS:528:DC%2BD1cXhsFWgsrfP
3. WA Daniel A Haduch M Syrek J Boksa 2006 Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment Eur Neuropsychopharmacol 16 8 580 587 16503401 10.1016/j.euroneuro. 2006.01.004 1:CAS:528:DC%2BD28Xht1ers7jN (Pubitemid 44716661)
4. TS Davies WM Kluwe 1998 Preclinical toxicological evaluation of sertraline hydrochloride Drug Chem Toxicol 21 4 521 537 10048942 10.3109/01480549809002220 1:CAS:528:DyaK1cXnslyks7g%3D
5. C DeBattista 2006 Augmentation and combination strategies for depression J Psychopharmacol 20 3 Suppl 11 18 16644767 10.1177/1359786806064310 1:CAS:528:DC%2BD28XlvVyjtLo%3D (Pubitemid 44605928)
6. C DeBattista HB Solvason J Poirier E Kendrick AF Schatzberg 2003 A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants J Clin Psychopharmacol 23 1 27 30 12544372 10.1097/00004714-200302000-00005 1:CAS:528:DC%2BD3sXmsVSnuw%3D%3D (Pubitemid 36164422)
7. JP Desager 1994 Clinical pharmacokinetics of ticlopidine Clin Pharmacokinet 26 5 347 355 8055680 10.2165/00003088-199426050-00003 1:CAS:528:DyaK2cXlsVyitrw%3D
8. CL DeVane HL Liston JS Markowitz 2002 Clinical pharmacokinetics of sertraline Clin Pharmacokinet 41 15 1247 1266 12452737 10.2165/00003088- 200241150-00002 1:CAS:528:DC%2BD3sXltFeisg%3D%3D (Pubitemid 36026765)
9. S Ekins SA Wrighton 1999 The role of CYP2B6 in human xenobiotic metabolism Drug Metab Rev 31 3 719 754 10461547 10.1081/DMR-100101942 1:CAS:528:DyaK1MXlvVKmsLc%3D (Pubitemid 29390407)
10. L Fan JC Wang F Jiang ZR Tan Y Chen Q Li W Zhang G Wang HP Lei DL Hu D Wang HH Zhou 2009 Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation Eur J Clin Pharmacol 65 4 403 409 19066872 10.1007/s00228-008-0594-3 1:CAS:528:DC%2BD1MXjt1Shs78%3D
11. A Haduch J Wojcikowski WA Daniel 2005 Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver Pharmacol Rep 57 6 774 781 16382196 1:CAS:528:DC%2BD28XjtlCks70%3D
12. A Haduch J Wojcikowski WA Daniel 2008 Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study Pharmacol Rep 60 6 957 965 19211989 1:CAS:528:DC%2BD1MXmtFaitrk%3D
13. LM Hesse K Venkatakrishnan MH Court LL von Moltke SX Duan RI Shader DJ Greenblatt 2000 CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants Drug Metab Dispos 28 10 1176 1183 10997936 1:CAS:528:DC%2BD3cXntVSltrs%3D
14. K Hirano R Kimura Y Sugimoto J Yamada S Uchida Y Kato H Hashimoto S Yamada 2005 Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors Br J Pharmacol 144 5 695 702 15678084 10.1038/sj.bjp.0706108 1:CAS:528:DC%2BD2MXisVSiu7g%3D (Pubitemid 40445618)
15. GW Hogeland S Swindells JC McNabb AD Kashuba GC Yee CM Lindley 2007 Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects Clin Pharmacol Ther 81 1 69 75 17186001 10.1038/sj.clpt.6100027 1:CAS:528:DC%2BD2sXht1aqsbs%3D (Pubitemid 46069599)
16. ED Kharasch D Mitchell R Coles R Blanco 2008 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir Antimicrob Agents Chemother 52 5 1663 1669 18285471 10.1128/AAC.01600-07 1:CAS:528:DC%2BD1cXls1ajtbk%3D (Pubitemid 351614658)
17. K Kobayashi T Ishizuka N Shimada Y Yoshimura K Kamijima K Chiba 1999 Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro Drug Metab Dispos 27 7 763 766 10383917 1:CAS:528: DyaK1MXkt1Cjs7Y%3D (Pubitemid 29297771)
18. M Kreilgaard DG Smith LT Brennum C Sanchez 2008 Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice Br J Pharmacol 155 2 276 284 18552871 10.1038/bjp.2008.243 1:CAS:528:DC%2BD1cXhtVygtL3F
19. SC Laizure CL DeVane JT Stewart CS Dommisse AA Lai 1985 Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose Clin Pharmacol Ther 38 5 586 589 3931955 10.1038/clpt.1985.228 1:CAS:528:DyaL28XksFarsg%3D%3D (Pubitemid 16193901)
20. AJ Lau TK Chang 2009 Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols Drug Metab Dispos 37 9 1931 1937 19487249 10.1124/dmd.109.028118 1:CAS:528:DC%2BD1MXhtVOrsrbL
21. JC Molnari HE Hassan BM Moeller AL Myers 2011 Drug interaction study between bupropion and ticlopidine in male CF-1 mice Biol Pharm Bull 34 3 447 451 21372402 10.1248/bpb.34.447 1:CAS:528:DC%2BC38XnvFCrsw%3D%3D
22. RS Obach LM Cox LM Tremaine 2005 Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study Drug Metab Dispos 33 2 262 270 15547048 10.1124/dmd.104.002428 1:CAS:528:DC%2BD2MXht1Cjtrw%3D (Pubitemid 40216594)
23. Rudkin L, Taylor MJ, Hawton K (2004) Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev (4):CD003382
24. G Shepherd 2005 Adverse effects associated with extra doses of bupropion Pharmacotherapy 25 10 1378 1382 16185182 10.1592/phco.2005.25.10.1378 1:CAS:528:DC%2BD2MXhtFGitb3M (Pubitemid 41407635)
25. RF Suckow TM Smith AS Perumal TB Cooper 1986 Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs Drug Metab Dispos 14 6 692 697 2877828 1:CAS:528:DyaL2sXktlerug%3D%3D (Pubitemid 17202408)
26. JC Talakad S Kumar JR Halpert 2009 Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs Drug Metab Dispos 37 3 644 650 19074527 10.1124/dmd.108.023655 1:CAS:528:DC%2BD1MXislamtbs%3D
27. MJ Taylor L Rudkin K Hawton 2005 Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials J Affect Disord 88 3 241 254 16162361 10.1016/j.jad.2005.07. 006 1:CAS:528:DC%2BD2MXhtFekur7O (Pubitemid 41446967)
28. M Turpeinen A Tolonen J Uusitalo J Jalonen O Pelkonen K Laine 2005 Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation Clin Pharmacol Ther 77 6 553 559 15961986 10.1016/j.clpt.2005.02.010 1:CAS:528:DC%2BD2MXlt1Gqt7k%3D (Pubitemid 40824968)
29. RL Walsky RS Obach 2007 A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6 Drug Metab Dispos 35 11 2053 2059 17682072 10.1124/dmd.107.015883 1:CAS:528:DC%2BD2sXht1Cnu7jN (Pubitemid 350005195)
30. RL Walsky AV Astuccio RS Obach 2006 Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6 J Clin Pharmacol 46 12 1426 1438 17101742 10.1177/0091270006293753 1:CAS:528:DC%2BD28XhtlajsbvL (Pubitemid 44704203)
31. JS Wang CL DeVane BB Gibson JL Donovan JS Markowitz HJ Zhu 2006 Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice Psychopharmacology (Berl) 183 4 490 499 10.1007/s00213-005-0209-y 1:CAS:528:DC%2BD2MXht1Knt7jO (Pubitemid 41721151)
32. RM Welch AA Lai DH Schroeder 1987 Pharmacological significance of the species differences in bupropion metabolism Xenobiotica 17 3 287 298 3107223 10.3109/00498258709043939 1:CAS:528:DyaL2sXktVShsrs%3D (Pubitemid 17039292)
33. S Zisook AJ Rush BR Haight DC Clines CB Rockett 2006 Use of bupropion in combination with serotonin reuptake inhibitors Biol Psychiatry 59 3 203 210 16165100 10.1016/j.biopsych.2005.06.027 1:CAS:528:DC%2BD28XhtlaqurY%3D (Pubitemid 43208965)